Latest Conference Coverage

Institutional Perspectives in Neurology, Chaired by Augusto Miravalle, MD

August 29th 2022

Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London. [WATCH TIME: 1 hour, 59 minutes]

Expanding on the Cognitive Stress Test and Answering Cognitive Deficit Questions: Rosie Curiel, PsyD

August 25th 2022

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]

The Realities of Gender-Targeted Therapeutics for Alzheimer Disease: Jessica Caldwell, PhD

August 21st 2022

The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]

Lessons About Alzheimer Disease and Related Dementias From GFAP, sTREM2 Astrocytes: Lynn Bekris, PhD

August 18th 2022

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed research on the use of GFAP and sTREM2 in discerning dementia with Lewy bodies from Alzheimer disease. [WATCH TIME: 4 minutes]

NeuroVoices: Jessica Caldwell, PhD, on Evaluating Brain Regions and Functional Connectivity to Understand Sex Differences in Cognitive Decline

August 17th 2022

The director of the Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed new research which looked at the differences in functional connectivity for men and women of older age.

Changes in Vocation as Early Signs for Alzheimer Disease, Cognitive Issues: Alvaro Pascual-Leone, MD, PhD

August 14th 2022

The chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]

Raising the Awareness of Severe Preeclampsia and Recognizing Potential Long-Term Impacts

August 13th 2022

Vesna Garovic, MD, PhD, chair of the nephrology division at Mayo Clinic, discussed the appropriate reaction to data suggesting late-life elevated inflammation and neurovascular damage from severe preeclampsia.

What Proactive Semantic Interference and Persistent PSI Can Reveal About Cognitive Status: Rosie Curiel, PsyD

August 12th 2022

The associate professor of neuropsychology at the University of Miami Miller School of Medicine provided insight on how persistent impairments seen on a cognitive screening tool may differentiate cognitive status. [WATCH TIME: 6 minutes]

Understanding the Cognitive Risks With Preeclampsia and Raising Awareness: Vesna Garovic, MD, PhD

August 11th 2022

The chair of the nephrology division at Mayo Clinic discussed the major questions surrounding preeclampsia and its long-term effects, as well as whether new findings change the way clinicians treat patients with the condition. [WATCH TIME: 4 minutes]

Incorporating Voice Analytics Into Cognitive Assessments: Alvaro Pascual-Leone, MD, PhD

August 7th 2022

The chief medical officer and cofounder of Linus Health provided insight on the outlook of acoustic measures and machine learning to further classify cognitive impairment. [WATCH TIME: 4 minutes]

Using Initial Cognitive Symptoms to Predict Trajectories of Neurodegenerative Pathologies

August 6th 2022

Jagan A. Pillai, MD, PhD, neurologist, Cleveland Clinic Lou Ruvo Center for Brain Health, discussed a recent study which found faster clinical progression in those with nonamnestic initial cognitive symptoms.

Risk of Incident Dementia Influenced by Apathy, Cognitive Status, and APOE Genotype in Mild Behavioral Impairment

August 5th 2022

Effect modification by cognitive status and APOE genotype revealed greater effects of mild behavioral impairment with apathy in those who had normal cognition or in non-APOE ɛ4 groups.

Using Nonamnestic Cognitive Symptoms to Predict Trajectories of Neurodegenerative Disorders: Jagan A. Pillai, MD, PhD

August 4th 2022

The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed new findings on whether initial cognitive symptoms have similar rates of functional decline across a handful of neurodegenerative disorders. [WATCH TIME: 3 minutes]

Plasma Neurofilament Light Levels Predict Poor Memory and Cognition, But Not Sleep, in Prodromal Alzheimer Stages

August 4th 2022

In addition to significant associations between executive memory and cognition, baseline neurofilament light levels and age trended toward significance.

Formulating the Right Combination of Acoustic Metrics to Quantify Cognitive Impairment: Alvaro Pascual-Leone, MD, PhD

August 3rd 2022

The chief medical officer and cofounder of Linus Health provided background on the reasoning for the measures used in a new machine learning algorithm that classifies cognitive status. [WATCH TIME: 3 minutes]

AAIC Expert Insight: Can Alzheimer Disease Be Treated With a Single-Target Approach?

August 3rd 2022

During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.

Cognition and Fall Risk Improved in Alzheimer Disease Following Exercise Program

August 3rd 2022

All severities of Alzheimer disease showed statistically significant benefits from the exercise program relative to controls, with more mild groups demonstrating the most improvement.

Crenezumab Fails to Meet Primary End Points in API ADAD Colombia Trial

August 2nd 2022

The monoclonal antibody that preferentially targets Aß oligomers failed to meet either of its coprimary end points—despite favorable results over the placebo group—in individuals who were unimpaired but at risk for AD.

Rare Missense Variant of APOE Shows Increased Risk of Alzheimer Disease in African Ancestry

August 2nd 2022

Using several large-scale cohorts, findings showed that cumulative incidence of Alzheimer disease grows faster with age in R145C variant carriers compared with noncarriers, contradicting prior research results.

Using Machine Learning, Speech Production to Quantify Mild Cognitive Impairment: Alvaro Pascual-Leone, MD, PhD

August 2nd 2022

The medical director of the Deanna and Sidney Wolk Center for Memory Health provided background on his new study using multimodal digital biomarkers to classify patients with mild cognitive impairment. [WATCH TIME: 5 minutes]

Post-COVID Cognitive and Functional Impairments Predicted by Anosmia, Not Infection Severity

August 1st 2022

Across the cohort, 11.6% of patients had impairments in memory, attention, and executive function; however, cognitive status was influenced by severity of anosmia, or loss of taste and smell.

© 2023 MJH Life Sciences

All rights reserved.